Carol Lynch: Addressing Misinformation About Biosimilars

Video

Carol Lynch, president of Sandoz US and head of North America, discusses which stakeholders have a role in addressing misinformation about biosimilars.

Transcript:

Who is responsible for addressing misinformation campaigns about biosimilars, and what can be done to stop them?

I think we all need to take on the task of tackling misinformation that’s out there, because I think, at best, it can lead to confusion for all stakeholders, and at worst, it can actually cause doubt about the safety and efficacy of biosimilars.

So, I think that from an FDA perspective they can definitely set out and help us with that. I think it’s on manufacturers to step up, but also the other players in the industry as well, so for example the medical societies, industry associations like [Association for Accessible Medicines] and Medicines for Europe, all play an important role in making sure that fair and balanced information is available to all stakeholders.

Related Videos
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.